Fennec Pharmaceuticals (FENC) Stock Price, Quote, News & History

Q: What sector and industry does Fennec Pharmaceuticals (FENC) operate in?

Fennec Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Comments

Fennec Pharmaceuticals (FENC) Stock Price, Quote, News & History

FENCNASDAQ

Logo brought to you by Benzinga Data

Trade with Public

$7.59

0.070.93%

At close: Jan 30, 4:00 PM EST

$7.59

N/A

After Hours: 4:01 PM EST

Overview

News Earnings Options Guidance Analyst Ratings Insider Trades Short Interest Stock Report

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Key Statistics

Open

$7.41

Close

$7.59

Volume / Avg.

132.08K / 158.06K

Day Range

$7.41 - $7.63

52 Wk Range

4.68 - 9.92

Market Cap

$259.23M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

48

Short Interest

3.04%

Days to Cover

3.66

Recent Fennec Pharmaceuticals Inc News

Pedmark Delivers In Japan Study — Less Hearing Loss, Same Cancer-Fighting Power

Pedmark cut cisplatin-related hearing loss in a Japan trial, with strong safety and no impact on tumor response, supporting plans for Japan registration.

Vandana Singh

Nasdaq, S&P 500 Hit 6-Month Lows As Recession Fears Grow: What's Driving Markets Monday?

Stocks extended last week's losses on Monday as concerns over the U.S. economy continue to weigh on the market. The Nasdaq 100 saw the steepest declines, with Tesla, Inc. (NASDAQ:TSLA) and Palantir Technologies, Inc.

Erica Kollmann

Why BP Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-7.99M

Investing Cash Flow (TTM)

-

Financing Cash Flow (TTM)

-10.39M

Free Cash Flow (TTM)

-7.99M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

-18.37M

Analyst Trends and Forecast

2

Aug 25

1

Jan

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.3

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$255.72M

PE Ratio (TTM)

-

PE Ratio (FWD)

11.60

PEG Ratio (TTM)

-

PS Ratio (TTM)

5.35

PB Ratio (TTM)

-

Earnings Yield % (TTM)

-3.45%

Earnings Yield % (FWD)

8.62%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

-$0.13

Company Debt

Total Debt

$19.38M

LT Debt

$19.38M

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$21.95M

Debt to Equity

-

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$7.41

Close

$7.59

Volume / Avg.

132.08K / 158.06K

Day Range

$7.41 - $7.63

52 Wk Range

4.68 - 9.92

Market Cap

$259.23M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

48

Short Interest

3.04%

Days to Cover

3.66

About

Sector

Health Care

Industry

Biotechnology

Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The comp...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Fennec Pharmaceuticals (FENC) stock?

A

You can purchase shares of Fennec Pharmaceuticals (NASDAQ:FENC) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Fennec Pharmaceuticals (FENC) competitors?

A

Other companies in Fennec Pharmaceuticals’s space includes: Cabaletta Bio Inc (NASDAQ:CABA), Voyager Therapeutics Inc (NASDAQ:VYGR), Immuneering Corp (NASDAQ:IMRX), Larimar Therapeutics Inc (NASDAQ:LRMR) and Armata Pharmaceuticals Inc (AMEX:ARMP).

Q

What is the forecast, or price target, for Fennec Pharmaceuticals (FENC) stock?

A

Fennec Pharmaceuticals has a consensus price target of $15.25.

Q

What is the current price for Fennec Pharmaceuticals (FENC)?

A

The stock price for Fennec Pharmaceuticals (NASDAQ: FENC) is $7.59 last updated January 30, 2026 at 4:01 PM EST.

Q

Does Fennec Pharmaceuticals (FENC) pay a dividend?

A

There are no upcoming dividends for Fennec Pharmaceuticals.

Q

When is Fennec Pharmaceuticals (NASDAQ:FENC) reporting earnings?

A

Fennec Pharmaceuticals does not have any upcoming earnings scheduled.

Q

Is Fennec Pharmaceuticals (FENC) going to split?

A

There is no upcoming split for Fennec Pharmaceuticals.

Q

What sector and industry does Fennec Pharmaceuticals (FENC) operate in?

A

Fennec Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch

Voyager Therapeutics Inc

Larimar Therapeutics Inc

NASDAQ:LRMR

$3.50

-1.12%

Armata Pharmaceuticals Inc

Enlivex Therapeutics Ltd

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Key Statistics

Open

$7.41

Close

$7.59

Volume / Avg.

132.08K / 158.06K

Day Range

$7.41 - $7.63

52 Wk Range

4.68 - 9.92

Market Cap

$259.23M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

48

Short Interest

3.04%

Days to Cover

3.66

Recent Fennec Pharmaceuticals Inc News

Pedmark Delivers In Japan Study — Less Hearing Loss, Same Cancer-Fighting Power

Pedmark cut cisplatin-related hearing loss in a Japan trial, with strong safety and no impact on tumor response, supporting plans for Japan registration.

Vandana Singh

Nasdaq, S&P 500 Hit 6-Month Lows As Recession Fears Grow: What's Driving Markets Monday?

Stocks extended last week's losses on Monday as concerns over the U.S. economy continue to weigh on the market. The Nasdaq 100 saw the steepest declines, with Tesla, Inc. (NASDAQ:TSLA) and Palantir Technologies, Inc.

Erica Kollmann

Why BP Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-7.99M

Investing Cash Flow (TTM)

-

Financing Cash Flow (TTM)

-10.39M

Free Cash Flow (TTM)

-7.99M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

-18.37M

Analyst Trends and Forecast

2

Aug 25

1

Jan

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.3

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$255.72M

PE Ratio (TTM)

-

PE Ratio (FWD)

11.60

PEG Ratio (TTM)

-

PS Ratio (TTM)

5.35

PB Ratio (TTM)

-

Earnings Yield % (TTM)

-3.45%

Earnings Yield % (FWD)

8.62%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

-$0.13

Company Debt

Total Debt

$19.38M

LT Debt

$19.38M

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$21.95M

Debt to Equity

-

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$7.41

Close

$7.59

Volume / Avg.

132.08K / 158.06K

Day Range

$7.41 - $7.63

52 Wk Range

4.68 - 9.92

Market Cap

$259.23M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

48

Short Interest

3.04%

Days to Cover

3.66

About

Sector

Health Care

Industry

Biotechnology

Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The comp...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry